An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
The purpose of this study is to determine the effectiveness of relatlimab plus nivolumab, alone or in combination with various standard-of-care treatments in participants with gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma that has come back or spread to other places in the body after prior therapy.
Gastric Cancer|Cancer of the Stomach|Stomach Cancer|Gastroesophageal Junction
BIOLOGICAL: Relatlimab + Nivolumab|BIOLOGICAL: Nivolumab|DRUG: Paclitaxel|DRUG: Ramucirumab
Overall response rate (ORR), Approximately 31 months
Incidence of adverse events (AEs), Approximately 5 years|Incidence of serious adverse events (SAEs), Approximately 5 years|Incidence of AEs leading to discontinuation, Approximately 5 years|Incidence of deaths, Approximately 5 years|Incidence of laboratory abnormalities, Approximately 5 years|ORR, Cohort A1, Approximately 5 years|Duration of response (DOR), Approximately 5 years|Progression free survival (PFS), Approximately 5 years|Overall survival (OS), Approximately 5 years
The purpose of this study is to determine the effectiveness of relatlimab plus nivolumab, alone or in combination with various standard-of-care treatments in participants with gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma that has come back or spread to other places in the body after prior therapy.